KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer

Timothy Corson, Qi Zhu Chang, Suzanne K. Lau, Frances A. Shepherd, Ming Sound Tsao, Brenda L. Gallie

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Purpose: The mitotic kinesin KIF14 is overexpressed in multiple cancers including lung cancer. Therefore, we investigated KIF14 expression in association with clinical variables and the effect of KIF14 on in vitro colony formation in non-small-cell lung carcinoma. Experimental Design: RNA was extracted from 129 untreated, resected tumors and KIF14 expression was quantified by real-time reverse transcription-PCR. Associations with clinical variables were determined by standard statistical methods. KIF14 expression was knocked down by small interfering RNA in H1299 and HeLa cells; proliferation and growth in soft agar were assayed. Results: Squamous cell carcinoma hadt he highest KIF14 level, followed by large-cell undifferentiated carcinoma, then adenocarcinoma (P = 0.002). KIF14 level decreased with differentiation (P = 0.01) but was not associated with pathologic stage, T or N stage, or sex. When dichotomized about the median, KIF14 overexpression significantly decreased disease-free survival (Kaplan-Meier log-rank, P = 0.01) and trended toward decreasing overall survival (P = 0.08). In a univariate Cox proportional hazard regression, increasing KIF14 expression decreased disease-free survival [P = 0.01; hazard ratio, 1.44 (95% confidence interval, 1.09-1.91)]. In a multivariate Cox regression, including stage, differentiation, histology, and tumor purity as covariates, KIF14 overexpression remained an independent prognostic factor for disease-free survival [P = 0.01; hazard ratio, 1.45 (95% confidence interval, 1.09-1.94)]. Knockdown of KIF14 in non-small-cell lung carcinoma and cervical carcinoma cell lines decreased proliferation and colony formation in soft agar. Conclusions: KIF14 expression is independently prognostic for disease-free survival in lung cancer and knockdown decreases tumorigenicity in vitro, showing that it is a clinically relevant oncogene and an exciting therapeutic target for further study.

Original languageEnglish (US)
Pages (from-to)3229-3234
Number of pages6
JournalClinical Cancer Research
Volume13
Issue number11
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

Disease-Free Survival
Lung Neoplasms
Messenger RNA
Non-Small Cell Lung Carcinoma
Agar
Confidence Intervals
Carcinoma
Large Cell Carcinoma
Kinesin
HeLa Cells
Oncogenes
Small Interfering RNA
Reverse Transcription
Squamous Cell Carcinoma
Neoplasms
Histology
Adenocarcinoma
Research Design
RNA
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. / Corson, Timothy; Chang, Qi Zhu; Lau, Suzanne K.; Shepherd, Frances A.; Tsao, Ming Sound; Gallie, Brenda L.

In: Clinical Cancer Research, Vol. 13, No. 11, 01.06.2007, p. 3229-3234.

Research output: Contribution to journalArticle

Corson, Timothy ; Chang, Qi Zhu ; Lau, Suzanne K. ; Shepherd, Frances A. ; Tsao, Ming Sound ; Gallie, Brenda L. / KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 11. pp. 3229-3234.
@article{f6977f23367e485b9276dd61efed3829,
title = "KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer",
abstract = "Purpose: The mitotic kinesin KIF14 is overexpressed in multiple cancers including lung cancer. Therefore, we investigated KIF14 expression in association with clinical variables and the effect of KIF14 on in vitro colony formation in non-small-cell lung carcinoma. Experimental Design: RNA was extracted from 129 untreated, resected tumors and KIF14 expression was quantified by real-time reverse transcription-PCR. Associations with clinical variables were determined by standard statistical methods. KIF14 expression was knocked down by small interfering RNA in H1299 and HeLa cells; proliferation and growth in soft agar were assayed. Results: Squamous cell carcinoma hadt he highest KIF14 level, followed by large-cell undifferentiated carcinoma, then adenocarcinoma (P = 0.002). KIF14 level decreased with differentiation (P = 0.01) but was not associated with pathologic stage, T or N stage, or sex. When dichotomized about the median, KIF14 overexpression significantly decreased disease-free survival (Kaplan-Meier log-rank, P = 0.01) and trended toward decreasing overall survival (P = 0.08). In a univariate Cox proportional hazard regression, increasing KIF14 expression decreased disease-free survival [P = 0.01; hazard ratio, 1.44 (95{\%} confidence interval, 1.09-1.91)]. In a multivariate Cox regression, including stage, differentiation, histology, and tumor purity as covariates, KIF14 overexpression remained an independent prognostic factor for disease-free survival [P = 0.01; hazard ratio, 1.45 (95{\%} confidence interval, 1.09-1.94)]. Knockdown of KIF14 in non-small-cell lung carcinoma and cervical carcinoma cell lines decreased proliferation and colony formation in soft agar. Conclusions: KIF14 expression is independently prognostic for disease-free survival in lung cancer and knockdown decreases tumorigenicity in vitro, showing that it is a clinically relevant oncogene and an exciting therapeutic target for further study.",
author = "Timothy Corson and Chang, {Qi Zhu} and Lau, {Suzanne K.} and Shepherd, {Frances A.} and Tsao, {Ming Sound} and Gallie, {Brenda L.}",
year = "2007",
month = "6",
day = "1",
doi = "10.1158/1078-0432.CCR-07-0393",
language = "English (US)",
volume = "13",
pages = "3229--3234",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer

AU - Corson, Timothy

AU - Chang, Qi Zhu

AU - Lau, Suzanne K.

AU - Shepherd, Frances A.

AU - Tsao, Ming Sound

AU - Gallie, Brenda L.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Purpose: The mitotic kinesin KIF14 is overexpressed in multiple cancers including lung cancer. Therefore, we investigated KIF14 expression in association with clinical variables and the effect of KIF14 on in vitro colony formation in non-small-cell lung carcinoma. Experimental Design: RNA was extracted from 129 untreated, resected tumors and KIF14 expression was quantified by real-time reverse transcription-PCR. Associations with clinical variables were determined by standard statistical methods. KIF14 expression was knocked down by small interfering RNA in H1299 and HeLa cells; proliferation and growth in soft agar were assayed. Results: Squamous cell carcinoma hadt he highest KIF14 level, followed by large-cell undifferentiated carcinoma, then adenocarcinoma (P = 0.002). KIF14 level decreased with differentiation (P = 0.01) but was not associated with pathologic stage, T or N stage, or sex. When dichotomized about the median, KIF14 overexpression significantly decreased disease-free survival (Kaplan-Meier log-rank, P = 0.01) and trended toward decreasing overall survival (P = 0.08). In a univariate Cox proportional hazard regression, increasing KIF14 expression decreased disease-free survival [P = 0.01; hazard ratio, 1.44 (95% confidence interval, 1.09-1.91)]. In a multivariate Cox regression, including stage, differentiation, histology, and tumor purity as covariates, KIF14 overexpression remained an independent prognostic factor for disease-free survival [P = 0.01; hazard ratio, 1.45 (95% confidence interval, 1.09-1.94)]. Knockdown of KIF14 in non-small-cell lung carcinoma and cervical carcinoma cell lines decreased proliferation and colony formation in soft agar. Conclusions: KIF14 expression is independently prognostic for disease-free survival in lung cancer and knockdown decreases tumorigenicity in vitro, showing that it is a clinically relevant oncogene and an exciting therapeutic target for further study.

AB - Purpose: The mitotic kinesin KIF14 is overexpressed in multiple cancers including lung cancer. Therefore, we investigated KIF14 expression in association with clinical variables and the effect of KIF14 on in vitro colony formation in non-small-cell lung carcinoma. Experimental Design: RNA was extracted from 129 untreated, resected tumors and KIF14 expression was quantified by real-time reverse transcription-PCR. Associations with clinical variables were determined by standard statistical methods. KIF14 expression was knocked down by small interfering RNA in H1299 and HeLa cells; proliferation and growth in soft agar were assayed. Results: Squamous cell carcinoma hadt he highest KIF14 level, followed by large-cell undifferentiated carcinoma, then adenocarcinoma (P = 0.002). KIF14 level decreased with differentiation (P = 0.01) but was not associated with pathologic stage, T or N stage, or sex. When dichotomized about the median, KIF14 overexpression significantly decreased disease-free survival (Kaplan-Meier log-rank, P = 0.01) and trended toward decreasing overall survival (P = 0.08). In a univariate Cox proportional hazard regression, increasing KIF14 expression decreased disease-free survival [P = 0.01; hazard ratio, 1.44 (95% confidence interval, 1.09-1.91)]. In a multivariate Cox regression, including stage, differentiation, histology, and tumor purity as covariates, KIF14 overexpression remained an independent prognostic factor for disease-free survival [P = 0.01; hazard ratio, 1.45 (95% confidence interval, 1.09-1.94)]. Knockdown of KIF14 in non-small-cell lung carcinoma and cervical carcinoma cell lines decreased proliferation and colony formation in soft agar. Conclusions: KIF14 expression is independently prognostic for disease-free survival in lung cancer and knockdown decreases tumorigenicity in vitro, showing that it is a clinically relevant oncogene and an exciting therapeutic target for further study.

UR - http://www.scopus.com/inward/record.url?scp=34250633168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250633168&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-0393

DO - 10.1158/1078-0432.CCR-07-0393

M3 - Article

C2 - 17545527

AN - SCOPUS:34250633168

VL - 13

SP - 3229

EP - 3234

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -